Use of paliperidone in elderly patients with schizophrenia and schizoaffective disorder: A prospective open-label short-term pilot study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 3, 2011, Pages 380-382

  Madhusoodanan, Subramoniam ^a,b   Brenner, Ronald ^a,b   Serper, Mark R ^a,c   Adelsky, Margarita ^c   Adler, David N ^a,b  

^a ST JOHN S EPISCOPAL HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c HOFSTRA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGING; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; OUTCOME ASSESSMENT; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM;

AGED; FEMALE; HUMANS; ISOXAZOLES; MALE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRIMIDINES; SCHIZOPHRENIA;

EID: 79955579282     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31821a12b2     Document Type: Letter

References (15)

1. Invega [product information]. Titusville, NJ: Janssen, LP. 2006.
2. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
3. Rockville GW, ed. Clinical Global Impressions, in ECDEU Assessment for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:217-222.
4. Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134: 382-389. (Pubitemid 9136500)
5. Chouinard G, Ross-Chouinard A, Annabel L, et al. The extrapyramidal symptom rating scale [abstract]. Can J Neurol Sci. 1980;7:233.
6. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183. (Pubitemid 13132147)
7. Tzimos A, Samokhvalov V, Kramer M, et al. safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open label extension. Am J Geriatr Psychiatry. 2008;16:31-43.
8. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162: 1010-1012. (Pubitemid 40676220)
9. Melkerson K. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol Clin Exp. 2006;21:529-532.
10. Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, et al. A randomized double-blind, placebo-controlled study of paliperidone in the treatment of subjects with schizoaffective disorder. Presented at: the US Psychiatric and Mental Health Congress in San Diego, CA, 2008.
11. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry. 1999;7(2): 132-138. (Pubitemid 29165462)
12. Madhusoodanan S, Suresh P, Brenner R, et al. Experience with atypical antipsychoticsVrisperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11(3):11-118.
13. Jeste DV, Barak Y, Madhusoodanan S, et al. International double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11(6):638-646.
14. Street JS, Tollefson GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly. Psychiatr Ann. 2000;30:191-196.
15. Davidson M, Harvey PD, Vervarcke CA, et al. A long-term, multicenter open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000;15:506-514. (Pubitemid 30409992)